Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

On June 2, 2022 Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) reported that members of the management team will participate in fireside chats at the following investor conferences (Press release, Deciphera Pharmaceuticals, JUN 2, 2022, View Source [SID1234615406]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Healthcare Conference on June 9, 2022 at 10:00 AM ET in New York, NY
JMP Securities Life Sciences Conference on June 15, 2022 at 10:00 AM ET in New York, NY
A live webcast of both events will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

Navigating Cancer in Collaboration with Experts in Oncology Present Key Research at 2022 ASCO Annual Meeting on Using Digital Health Solutions to Bridge the Health Equity Gap

On June 2, 2022 Navigating Cancer in collaboration with Texas Oncology reported that executes large-scale patient engagement study revealing high digital health solution engagement while demonstrating the opportunity to increase support for diverse patient populations (Press release, Navigating Cancer, JUN 2, 2022, View Source [SID1234615422]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scientific and technological advancements have helped enhance cancer care and access to care. Indeed, an important silver lining in the pandemic has been the acceleration of adoption of virtual care and related digital health technologies. But these innovations have also helped highlight gaps and inequities that challenge healthcare providers and other stakeholders. Aligned with the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting theme, Advancing Equitable Cancer Care Through Innovation, Navigating Cancer in collaboration with Texas Oncology, will present key research evaluating the benefits and need for digital health solutions (DHS) across all patient populations.

These abstracts are a continuation of research Navigating Cancer and Texas Oncology presented in 2021 that addresses digital health equity, and specifically, the crucial question: Are we making digital health solutions accessible and supportive to all patient populations?

Communities that experience gaps in care are often underrepresented at the point of product, service, and program design, creating inefficiencies for healthcare professionals (communication and care barriers) and accessibility obstacles (language, internet/device access, insurance, etc.) for patients.

The goal of this study was to gather data to develop insights into these key access-related challenges, including the significant barriers facing rural, elderly, and Spanish-speaking communities interacting with digital health solutions and care teams, as well as other insights from implementing DHS across a large, geographically dispersed community-based practice.

Findings presented during the Podium Presentation, Evaluating mass implementation of digital health solutions to improve quality and reduce disparities in a large multisite community oncology practice (Abstract #1575) and the follow-up study (poster presentation), Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice (Abstract #1575), offer insights into these key challenges.

"Working harder than we ever have to serve patients in the last two years, I’m so excited to see how digital health tools are improving the patient journey,"

– Debra Patt, MD, Ph.D., MBA, Texas Oncology

Findings from the research highlight the benefits of DHS in improving the patient journey, while demonstrating the additional value derived from Navigating Cancer’s broad ability to improve clinical outcomes and capture longitudinal data that provides engagement insights.

"It is gratifying to see a highly successful implementation of patient-centered digital care enhancements in a large and leading oncology practice in the US which provides an exemplar for other practices towards the future," said Ethan Basch, MD, MSc, University of North Carolina.

Outcomes
Sociodemographic data coupled with digital engagement insights from Texas Oncology’s large, diverse patient population reveal an important disparity among segments of the patient population related to the so-called "digital divide." In this context, access and ability to use internet technology, language barriers and other sociodemographic determinants underlie health disparity and equity challenges.

In our two highlighted abstracts, researchers were equipped with data from Texas Oncology’s 220 sites of service with total sample size populations spanning both 100,888 and 283,000 unique cancer patients, respectively.

Evaluating mass implementation of digital health solutions to improve quality and reduce disparities in a large multisite community oncology practice (Abstract #1507):
In this oral presentation (details below), Navigating Cancer highlights insights from a longitudinal (3-year) observational study of DHS implementation across a multi-site community practice covering over 280,000 cancer patients. In this study, the researchers observed high engagement across the digital health solution, including rates of 83%, 68%, and 57% for the patient portal, remote monitoring, and digital education, respectively. Additionally, there was positive engagement among groups typically vulnerable to equitable digital engagement, including the older age demographic and patients living in rural settings. While there was active engagement among non-English language patients, the authors note that opportunities exist to improve engagement among racial/ethnic minorities and individuals without English-language preference.
Analyzing patient engagement with digital health tools to facilitate equity across a large statewide community oncology practice (Abstract #1575):
In this poster presentation (details below), researchers at Navigating Cancer and Texas Oncology focused on understanding differences in digital activity rates based on various sociodemographic factors across tools within the DHS. The authors observed high overall rates of digital activity, including a 64% read rate for digital education, 55% compliance rate with ePRO remote monitoring, and an average of 1 portal/login per week. Additionally, despite variable engagement across age, rural status, and language preference, patients within these groups continue to utilize the DHS. Specifically, despite language barriers, the engaged population were interested in consuming patient education on the DHS. This was demonstrated by the fact that among patients that had read at least one education article, the overall read rate was 96%. The authors concluded that additional tool optimization for patient-specific barriers should be addressed in the future.
Navigating Cancer will continue, alongside our advisors, to support equitable care innovation through research and dialogue to better understand and listen to patient voices that may go unheard. Research being presented this year demonstrates the need to close gaps in care related to language barriers through translation of patient education information, and more availability of translated materials at the point of product, service, and program design.

Navigating Cancer is committed to pushing forward a technology roadmap that addresses digital health equity. "In addition to highlighting digital health divides in oncology, the accepted abstracts also demonstrate the power of collaboration between clinicians and technology vendors in bridging the gaps in transformative and innovative cancer care delivery, " said Amila Patel, PharmD, BCOP.

Curis to Present at 2022 Jefferies Global Healthcare Conference

On June 2, 2022 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:00 a.m. in New York, NY (Press release, Curis, JUN 2, 2022, View Source [SID1234615440]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company’s website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

Median Technologies to Present an Abstract at the 2022 ASCO Annual Meeting, June 3 – 7, 2022, McCormick Place, Chicago, IL, USA

On June 2, 2022 Median Technologies (ALMDT) reported that it will be presenting an abstract at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting, June 3-7, McCormick Place, Chicago, IL, USA (exhibition dates: June 4-6) (Press release, MEDIAN Technologies, JUN 2, 2022, View Source [SID1234615456]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the session include:

Abstract # / Poster # – The adjudication rates between readers in Blinded Independent Central Review (BICR) of advanced esophageal cancer trials with or without immune checkpoint initiators as first-line therapy

Session: Gastrointestinal Cancer, Gastroesophageal, Pancreatic and Hepatobiliary
Date: Saturday June 4, 2022
Time: 8:00 AM – 11:00 AM CDT
Place: McCormick Place South, Hall A, Poster Board 27

The study analyzed a pool of advanced esophageal cancer trials with or without immune checkpoint inhibitors, which used RECIST 1.1, and documented the proportion of reader discrepancies, reader performance through monitoring procedures. 4 esophageal cancer BICR trials that included 1,875 patients (8,501 time-points) involving 14 radiologists were analyzed. Trials had an average adjudication rate of 45.28%. The discordances of baseline lesion selection (34.4% of discordances) and lesion measurement (40.3% of discordance) in follow up visits are the main reasons triggering adjudications in esophageal cancer central reading. Appropriate reader training and monitoring are solutions which can not only mitigate a large portion of the commonly encountered reading errors, but also help to reach more consensus on lesion selection and measurement between readers.

The Median’s clinical team will be available at booth #2098, Exhibit Hall A to discuss the abstract results from June 4 to June 6, 9:00 am-5:00 pm.

The ASCO (Free ASCO Whitepaper) Annual Meeting is the world’s premier oncology conference, organized by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), the largest oncology society in the world. Each year, the ASCO (Free ASCO Whitepaper) conference brings together more than 35,000 oncologists from all around the globe, and is attended by all medical, educational and industrial stakeholders involved in the field of oncology worldwide. More about the ASCO (Free ASCO Whitepaper) Annual Meeting: View Source

TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering

On June 2, 2022 TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, reported the pricing of an underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting discounts and commissions, and other offering expenses (Press release, TC Biopharm, JUN 2, 2022, View Source [SID1234615473]). In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 ADSs at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is expected to close on or about June 7, 2022, subject to satisfaction of customary closing conditions.

EF Hutton, division of Benchmark Investments, LLC, is acting as sole book-running manager for the offering.

A registration statement on Form F-1 (File No. 333-265159), was filed with the Securities and Exchange Commission ("SEC") and was declared effective on June [2], 2022. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at View Source Electronic copies of the final prospectus relating to this offering, when available, may be obtained from EF Hutton, division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor, New York, NY 10022, Attention: Syndicate Department, or via email at [email protected] or telephone at (212) 404-7002.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.